Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AVBP

ArriVent BioPharma Inc.

Apr 26 • 04:00PM ET

15.44

Dollar change -0.10
Percentage change -0.64	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO IWO IWC SCHB VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	36.81%	Shs Outstand	33.49M	Perf Week	-0.39%
Market Cap	517.09M	Forward P/E	-	EPS next Y	-2.41	Insider Trans	18.09%	Shs Float	21.17M	Perf Month	-14.22%
Income	-96.02M	PEG	-	EPS next Q	-1.02	Inst Own	18.91%	Short Float	4.46%	Perf Quarter	-22.80%
Sales	0.00M	P/S	-	EPS this Y	88.25%	Inst Trans	-	Short Ratio	4.12	Perf Half Y	-
Book/sh	-4.57	P/B	-	EPS next Y	36.77%	ROA	-	Short Interest	0.94M	Perf Year	-
Cash/sh	4.49	P/C	3.44	EPS next 5Y	-	ROE	-	52W Range	14.35 - 25.95	Perf YTD	-22.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.39%	52W High	-40.50%	Beta	-
Dividend TTM	-	Quick Ratio	13.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	7.60%	ATR (14)	1.18
Dividend Ex-Date	-	Current Ratio	13.76	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	34.04	Volatility	8.02% 6.38%
Employees	40	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-80.05%	Payout	-	Rel Volume	0.23	Prev Close	15.54
Sales Surprise	-	EPS Surprise	-7.69%	Sales Q/Q	-	Earnings	Mar 28 AMC	Avg Volume	229.18K	Price	15.44
SMA20	-8.92%	SMA50	-16.97%	SMA200	-19.52%	Trades		Volume	53,529	Change	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01 04:47 PM
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31 04:10 PM
GORDON CARL L	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:11 PM
ORBIMED ADVISORS LLC	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc.

Upgrade your FINVIZ experience